Pro-caspase-3 overexpression sensitises ovarian cancer cells to proteasome inhibitors

T Tenev1, M Marani, I McNeish

  • 1ICRF Molecular Oncology Unit, Imperial College School of Medicine at Hammersmith Hospital, London W12 ONN, UK.

Insights

Proteasome inhibitors induce apoptosis in ovarian cancer cells by activating caspase-3. Overexpressing pro-caspase-3 sensitizes these cells, suggesting a combined therapeutic strategy for cancer treatment.

Area of Science:

  • Cell Biology
  • Molecular Biology
  • Cancer Research

Background:

  • The ubiquitin-proteasome pathway is crucial for cell cycle regulation.
  • Dysregulation of this pathway can inhibit cell proliferation and induce apoptosis.
  • Proteasome inhibitors are explored as anti-cancer drug targets.

Purpose of the Study:

  • To investigate the mechanism of apoptosis induced by proteasome inhibitors (MG-132, lactacystin, ALLN).
  • To determine the role of pro-caspase-3 in sensitizing ovarian cancer cells to proteasome inhibitor-induced apoptosis.

Main Methods:

  • Treatment of HEK 293, SKOV3, and OVCAR3 cell lines with proteasome inhibitors.
  • Generation of stable SKOV3 and OVCAR3 cell lines with inducible pro-caspase-3 expression using a tetracycline-responsive system.
  • Assessment of caspase activation and apoptosis induction.

Main Results:

  • MG-132 treatment activated caspase-3 and caspase-6 in HEK 293 cells.
  • Inducible pro-caspase-3 expression alone did not induce apoptosis.
  • Co-treatment with proteasome inhibitors and pro-caspase-3 overexpression led to rapid apoptosis in ovarian cancer cells.

Conclusions:

  • Pro-caspase-3 sensitizes ovarian cancer cells to proteasome inhibitor-induced apoptosis.
  • Combining proteasome inhibitors with strategies to enhance pro-caspase-3 may offer a novel therapeutic approach for ovarian and other cancers.